AU2024278298A1 — Use of migalastat for treating fabry disease in pregnant patients
Assigned to Amicus Therapeutics Inc · Expires 2025-01-09 · 1y expired
What this patent protects
The present invention relates to a method for the treatment of Fabry disease in a pregnant patient, or a female patient of childbearing potential, comprising administering to the patient a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg f…
USPTO Abstract
The present invention relates to a method for the treatment of Fabry disease in a pregnant patient, or a female patient of childbearing potential, comprising administering to the patient a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg free base equivalent (FBE) of migalastat or a salt thereof at a frequency of once every other day.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.